glp 1 and muscle mass loss GLP-1 Loss: Semaglutide, Tirzepatide & Lean A Hidden Consequence of GLP-1s:

Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy

One in three Philadelphians are living with obesity, putting them at higher risk of chronic conditions like diabetes and heart disease, but these days fewer are seeking the bariatric surgical procedures long considered a leading medical treatment for the condition

Image Credit: Juan Gaertner / Shutterstock.com Introduction Emerging evidence suggests that specific foods, nutrients, and lifestyle habits can stimulate the release of glucagon-like peptide 1 (GLP-1), improve appetite control, and support cardiometabolic balance

The compounding market includes companies like telehealth business Hims & Hers, which are selling GLP-1s made from similar ingredients but arent branded, FDA-approved drugs

The reckoning for investors arrived on August 5, 2025, when a dramatic lowering of the full-year guidance triggered a massive sell-off

Whats clear is that individual response varies widely, reinforcing the need for personalization